CY1112689T1 - Συνθεση για τη βελτιωση της γνωσης και της μνημης - Google Patents

Συνθεση για τη βελτιωση της γνωσης και της μνημης

Info

Publication number
CY1112689T1
CY1112689T1 CY20121100327T CY121100327T CY1112689T1 CY 1112689 T1 CY1112689 T1 CY 1112689T1 CY 20121100327 T CY20121100327 T CY 20121100327T CY 121100327 T CY121100327 T CY 121100327T CY 1112689 T1 CY1112689 T1 CY 1112689T1
Authority
CY
Cyprus
Prior art keywords
melatonin
nicotine
treatment
active ingredient
insomnia
Prior art date
Application number
CY20121100327T
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharmaceuticals (1991) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Limited filed Critical Neurim Pharmaceuticals (1991) Limited
Publication of CY1112689T1 publication Critical patent/CY1112689T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά φαρμακολογικώς δραστικό συνδυασμό, που έχει χρησιμότητα στη θεραπευτική αγωγή ασθενών με αϋπνία, ο οποίος περιλαμβάνει: (α) τουλάχιστον ένα πρώτο δραστικό συστατικό που επιλέγεται από μελατονίνη, άλλους μελατονινεργικούς παράγοντες, αγωνιστές μελατονίνης και ανταγωνιστές μελατονίνης, και (β) τουλάχιστον ένα δεύτερο δραστικό συστατικό που επιλέγεται από νικοτίνη και αγωνιστές υποδοχέων νικοτίνης, τη χρήση φαρμάκου που περιέχει το συστατικό (α) με ή χωρίς το συστατικό (β) για την ανακούφιση τουλάχιστον ενός ανεπιθύμητου αποτελέσματος το παρουσιάζεται σε ασθενή στην πορεία θεραπείας αντικατάστασης της νικοτίνης, ή διαφορετικά, που επιλέγεται από την εξασθένιση της ποιότητας ύπνου, την εξασθένιση της γνώσης και την εξασθένιση της μνήμης, καθώς επίσης σετ εργαλείων που έχουν χρησιμότητα στη θεραπευτική αγωγή ασθενών με αϋπνία, το οποίο αποτελείται από τα συστατικά (α) και (β) στη μορφή δόσης μονάδας.
CY20121100327T 2003-04-29 2012-04-02 Συνθεση για τη βελτιωση της γνωσης και της μνημης CY1112689T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment
EP04727667A EP1620058B1 (en) 2003-04-29 2004-04-15 Composition for improving cognition and memory

Publications (1)

Publication Number Publication Date
CY1112689T1 true CY1112689T1 (el) 2016-02-10

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100327T CY1112689T1 (el) 2003-04-29 2012-04-02 Συνθεση για τη βελτιωση της γνωσης και της μνημης

Country Status (29)

Country Link
US (2) US8859593B2 (el)
EP (1) EP1620058B1 (el)
JP (2) JP4981440B2 (el)
KR (1) KR101136885B1 (el)
CN (1) CN1787820B (el)
AR (1) AR048370A1 (el)
AT (1) ATE539746T1 (el)
BR (1) BRPI0409935A (el)
CA (1) CA2521182C (el)
CL (1) CL2004000877A1 (el)
CY (1) CY1112689T1 (el)
DK (1) DK1620058T3 (el)
EA (1) EA008768B1 (el)
ES (1) ES2380364T3 (el)
HK (1) HK1087635A1 (el)
IL (1) IL155666A (el)
IS (1) IS8090A (el)
MX (1) MXPA05011590A (el)
NO (1) NO333015B1 (el)
NZ (1) NZ542724A (el)
PE (1) PE20050144A1 (el)
PL (1) PL1620058T3 (el)
PT (1) PT1620058E (el)
SI (1) SI1620058T1 (el)
TW (1) TWI340037B (el)
UA (1) UA87980C2 (el)
UY (1) UY28296A1 (el)
WO (1) WO2004096118A2 (el)
ZA (1) ZA200509508B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
EP2124907B1 (en) 2007-03-19 2018-05-30 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
BRPI0811052A2 (pt) * 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
KR102411809B1 (ko) 2012-01-26 2022-06-22 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3767297A1 (en) * 2012-12-18 2021-01-20 Vanda Pharmaceuticals Inc. Method of determining tau and thereby determining whether a patient has a free-running circadian rhythm
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3253378B1 (fr) * 2015-02-04 2019-05-08 Soeur Josefa Menendez Système thérapeutique transdermique contenant de la valentonine et son utilisation comme médicament
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4680172A (en) 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
ES2028074T3 (es) 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
AU660336B2 (en) * 1991-10-18 1995-06-22 Alza Corporation Device for the transdermal administration of melatonin
JPH07506720A (ja) * 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
IL105240A (en) * 1992-04-07 1999-04-11 Neurim Pharma 1991 The use of melatonin in the preparation of a drug for the treatment of benign prostatic hyperplasia
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
EP0708627B1 (en) * 1993-07-09 2000-02-02 Cygnus, Inc. Method and device for providing nicotine replacement therapy transdermally/transbuccally
EP0755244A1 (en) * 1994-04-13 1997-01-29 Novartis AG Temporally controlled drug delivery systems
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996023496A1 (en) 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
US5696115A (en) 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
DK0906089T3 (da) * 1996-05-13 2003-12-08 Novartis Consumer Health Sa Mundafgivelsessystem
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0984970B1 (en) * 1997-05-30 2003-11-19 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AU3364499A (en) * 1998-03-25 1999-10-18 New York University Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU5787999A (en) * 1998-08-26 2000-03-21 Andrei Zakharovich Afanasiev Method for treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DK1150661T3 (da) 1999-02-05 2004-03-01 Cipla Ltd Topiske sprays der omfatter et filmdannende præparat
US6353051B1 (en) * 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
EE200200379A (et) 2000-01-05 2003-10-15 Neurim Pharmaceuticals (1991) Ltd. Meetod ja preparaat antihüpertensiivsete ainete suhtes resistentsuse ja sellega seotud haigusseisundite raviks
EP2140868A1 (en) * 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2001282873A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002076211A1 (en) 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
DE60105820D1 (de) * 2001-10-22 2004-10-28 Pera Ivo E Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit
US7113651B2 (en) * 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
EP1620058A2 (en) 2006-02-01
HK1087635A1 (en) 2006-10-20
IL155666A0 (en) 2004-09-27
US20140378512A1 (en) 2014-12-25
EA200501666A1 (ru) 2006-06-30
PE20050144A1 (es) 2005-05-12
ZA200509508B (en) 2006-11-29
IL155666A (en) 2013-12-31
WO2004096118B1 (en) 2005-12-01
ATE539746T1 (de) 2012-01-15
KR20060005402A (ko) 2006-01-17
CN1787820B (zh) 2010-05-05
NO20055531L (no) 2005-11-23
JP2006525317A (ja) 2006-11-09
WO2004096118A2 (en) 2004-11-11
PL1620058T3 (pl) 2012-07-31
SI1620058T1 (sl) 2012-05-31
TWI340037B (en) 2011-04-11
NO333015B1 (no) 2013-02-18
CL2004000877A1 (es) 2005-01-07
AR048370A1 (es) 2006-04-26
JP4981440B2 (ja) 2012-07-18
NZ542724A (en) 2007-05-31
TW200501948A (en) 2005-01-16
IS8090A (is) 2005-10-25
CA2521182A1 (en) 2004-11-11
BRPI0409935A (pt) 2006-04-25
JP2012116859A (ja) 2012-06-21
WO2004096118A3 (en) 2005-10-13
CN1787820A (zh) 2006-06-14
EA008768B1 (ru) 2007-08-31
US20060229340A1 (en) 2006-10-12
EP1620058B1 (en) 2012-01-04
UY28296A1 (es) 2004-11-30
MXPA05011590A (es) 2006-03-08
UA87980C2 (ru) 2009-09-10
US8859593B2 (en) 2014-10-14
DK1620058T3 (da) 2012-05-07
PT1620058E (pt) 2012-04-13
KR101136885B1 (ko) 2012-04-20
CA2521182C (en) 2011-05-31
EP1620058A4 (en) 2006-07-26
ES2380364T3 (es) 2012-05-11

Similar Documents

Publication Publication Date Title
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
CY1108018T1 (el) Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
CY1111880T1 (el) Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
CY1118179T1 (el) Φαρμακευτικη συνθεση
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
CY1106225T1 (el) Διαδικασια για την παρασκευη της 2-μεθυλ πιπepαζινης
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
CY1109001T1 (el) Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz